Alopecia hair loss treatments

alopecia trial

CTP-543 is Being Evaluated in Moderate-to-Severe Alopecia Areata

/in , , /by

Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial

CTP-543 is Being Evaluated in Moderate-to-Severe Alopecia Areata

Phase 2a Trial On Track to Complete in Second Half of 2018

Concert Pharmaceuticals, Inc today announced that it has completed enrollment of the first cohort of its Phase 2a trial evaluating CTP-543.
Concert is developing CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss.
CTP-543 is a deuterium-modified analog of ruxolitinib, a Janus Kinase (JAK) inhibitor that is commercially available under the brand name Jakafi® for the treatment of certain blood disorders.

In the Phase 2a trial, patients with alopecia areata in the first cohort are administered 4 mg of CTP-543 or placebo twice daily for 24 weeks.

An independent Data Monitoring Committee (DMC) will conduct an interim safety data review from the first cohort after patients have completed three months of dosing. This review is expected to be completed in the first quarter of 2018.

Based on this review, the DMC will provide its recommendation regarding initiating the second cohort in the trial, which will be administered 8 mg of CTP-543 or placebo twice daily for 24 weeks. The Phase 2a trial is expected to be completed in the second half of 2018.

“We are excited to see the enthusiastic participation by alopecia areata patients in our study.

Its sequential dosing design will allow us to assess the safety and efficacy of CTP-543 in this disease in a controlled and deliberate manner,” said James Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. “We look forward to the DMC’s assessment, and we are on track with our goal to complete the trial in the second half of 2018.”

The Phase 2a trial is a double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of CTP-543 in adults with moderate-to-severe alopecia areata. Approximately 90 patients are being enrolled in the study and sequentially randomized to receive one of two doses of CTP-543 (4 or 8 mg) or placebo twice daily.

The primary outcome measure will utilize the severity of alopecia tool (SALT) after 24 weeks of dosing. Patient-reported outcome measures will be assessed as secondary endpoints. If appropriate, the protocol may be amended to explore higher doses of CTP-543.

Additional information about the trial is available on www.clinicaltrials.gov.

CTP-543 has been well-tolerated in clinical evaluation to date and has demonstrated a non-clinical safety profile consistent with therapeutic JAK inhibition.

About CTP-543 and Alopecia Areata

CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib, a drug which selectively inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available under the name Jakafi® in the United States for the treatment of certain blood disorders.

Ruxolitinib has been used to treat alopecia areata in academic settings, including an investigator-sponsored clinical trial, and has been reported to promote hair growth in individuals with moderate-to-severe disease.

Ruxolitinib and Alopecia Trial

Ruxolitinib Alopecia Study

Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men.

Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) meeting in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

The meeting was held on Monday, September 11, 2017. Additional information is available online at: https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm554443.htm

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company’s approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com.

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Source

Alopecia Trial

alopecia research

Global Alopecia Drugs Market to increase rapidly by 2022

/in /by

Global Alopecia Drugs Market to increase rapidly by 2022

Alopecia Drugs Industry, 2012-2022 Market Research Report’ is a professional and in-depth study on the current state of the global Alopecia Drugs industry with a focus on the Chinese market.

The report provides key statistics on the market status of the Alopecia Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology.

Browse complete report at www.researchtrades.com/report/global-and-chinese-alopecia…

Through the statistical analysis, the report depicts the global and Chinese total market of Alopecia Drugs industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2017-2022 market development trends of Alopecia Drugs industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Alopecia Drugs Industry before evaluating its feasibility.

Overall, the report provides an in-depth insight of 2012-2022 global and Chinese Alopecia Drugs industry covering all important parameters.

Chapter One Introduction of Alopecia Drugs Industry

1.1 Brief Introduction of Alopecia Drugs
1.2 Development of Alopecia Drugs Industry
1.3 Status of Alopecia Drugs Industry

Chapter Two Manufacturing Technology of Alopecia Drugs

2.1 Development of Alopecia Drugs Manufacturing Technology
2.2 Analysis of Alopecia Drugs Manufacturing Technology
2.3 Trends of Alopecia Drugs Manufacturing Technology

Chapter Three Analysis of Global Key Manufacturers

3.1 Company A
3.1.1 Company Profile
3.1.2 Product Information
3.1.3 2012-2017 Production Information
3.1.4 Contact Information
3.2 Company B
3.2.1 Company Profile
3.2.2 Product Information
3.2.3 2012-2017 Production Information
3.2.4 Contact Information
3.3 Company C
3.2.1 Company Profile
3.3.2 Product Information
3.3.3 2012-2017 Production Information
3.3.4 Contact Information
3.4 Company D
3.4.1 Company Profile
3.4.2 Product Information
3.4.3 2012-2017 Production Information
3.4.4 Contact Information
3.5 Company E
3.5.1 Company Profile
3.5.2 Product Information
3.5.3 2012-2017 Production Information
3.5.4 Contact Information
….
Research Trades has team of experts who works on providing exhaustive analysis pertaining to market research on a global basis. This comprehensive analysis is obtained by a thorough research and study of the ongoing trends and provides predictive data regarding the future estimations, which can be utilized by various organizations for growth purposes.

We distribute customized reports that focus on meeting the client’s specific requirement. Our database consists of a large collection of high-quality reports obtained using a customer-centric approach, thus providing valuable research insights.

Source

Global Alopecia Drugs Market to increase rapidly by 2022

hair loss supplements

Pediatric Alopecia Areata Severity Linked to Serum Vitamin D

/in /by

Pediatric Alopecia Areata Severity Linked to Serum Vitamin D

For pediatric patients with alopecia areata, vitamin D is negatively correlated with disease severity, number of patches, and disease duration, according to a study published online in the Journal of Cosmetic Dermatology.

Mehmet Unal, MD, and Gulsum Gonulalan, MD, from the Konya Numune Hospital in Turkey, examined vitamin D status in 20 pediatric patients with alopecia areata and 34 pediatric healthy controls. The authors assessed the correlation between vitamin D status and disease severity, number of patches, and disease duration.

The researchers found that the mean serum 25-hydroxyvitamin D concentration was 15.47±7.66 and 11.09±10.53 ng/mL in patients and controls, respectively; no statistically significant difference was seen between the groups (P =.084).

Significant, negative correlations were seen for vitamin D concentration with the Severity of Alopecia Tool score (P <.001; r, -0.831), number of patches (P <.001; r, -0.989), and disease duration (P <.001 and r, -0.997).

“Vitamin D deficiency is not the only etiologic factor in alopecia areata pathogenesis, but in the presence of other etiological factors, this deficiency can aggravate alopecia areata severity, and thus, vitamin D supplementation may be beneficial in treatment of pediatric alopecia areata,” the authors write.

Source

alopecia research

Alopecia Treatment Market Significant Profits Estimated to be Generated by 2022

/in /by

Alopecia (Hair Loss)Treatment Market Significant Profits Estimated to be Generated by 2022

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. Sedentary lifestyle, and unhealthy diets is leading to loss of hair among masses.

Furthermore, ageing and hormonal imbalance, increasing chronic disease like arthritis, cancer, hypertension, depression also leads to hair loss especially among middle aged population.

According to American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men.  Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide.

A sample of this report is available upon request @   https://www.persistencemarketresearch.com/samples/9677

For the treatment of alopecia, U.S. FDA proved two drugs – Minoxidil, to treat hypertension and finasteride (Propecia) to treat benign prostate hyperplasia (BPH). American Hair Loss Association recommends the use of minoxidil in patients who have not responded to finasteride treatment. Prevalence rate of alopecia is high among working age population.

Propecia hair loss

Treatment seeking rate for alopecial is more prevalent in developed regions as compared to that in developing regions, however, over the past few years, demand for alopecia treatment has increased dramatically in developing regions such as China and India owing to increase in healthcare expenditure and improved healthcare infrastructure facilities. In China, 6 percent females and 21 percent of males suffer from hormone driven hair loss.

Changing lifestyle along with increase in stress level among working class population is expected to boost the demand for treatment of hair loss globally.

Furthermore, rise in geriatrics population along with high demand for surgical hair transplant is expected to drive the alopecia treatment market. Increasing consumer disposable incomes and health awareness, emphasis to look good, and technological advancement in hair treatment medical devices are some other key drivers for this market.

Since accessibility for scalp treatment is easily accessible and available, the demand for alopecia treatment has increased.

Though the market is expected to witness healthy growth during the forecast period, high cost of the medications and possible side effects/allergic reactions are acting as key barrier for alopecia market.

Alopecia Treatment Market is broadly classified on the basis of the following segments –

Alopecia Treatment Market by Product:

Vitamins and Supplements
Shampoos and Conditioners
Others (Serums, gels and oils)

Alopecia Treatment Market by Gender:

Men
Women
Children

Alopecia Treatment Market by End User:

Homecare Settings
Dermatology Clinics
Others (Salons)

The alopecia treatment market has grown substantially at a healthy CAGR due to changing lifestyle and greater emphasis on outward appearance to look good. With rapid technological advancement and innovation, alopecia treatment market is expected to grow globally.

North America is the largest market for alopecia treatment while Asia Pacific is expected to be the fastest growing market during the forecast period.

The alopecia treatment market is expected to register a significant CAGR during the forecast period. Depending on geographic regions, alopecia treatment is segmented into seven key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America, followed by Europe, is expected to dominate the alopecia treatment market throughout the forecast period.

Asia Pacific excluding Japan is poised to witness fastest growth owing to outburst of middle aged population in the region. Also, the region is witnessing healthy growth in terms of GDP, which in turn is expected to propel growth at healthy digits. Middle East & Africa and Latin America are expected to sluggish growth during the forecast period.

Some of the key market players for alopecia treatment market are Cipla, Viviscal, Dr. Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr. Kurt Wolff GmbH & Co. KG, Rogaine – Johnson and Johnson.

Source

Alopecia Awareness Week

Alopecia Awareness Week

/in /by

Alopecia Awareness Week: How wigs can help children with the condition feel more confident

STELLA Hammet was five years old when her hair started falling out.

The 12-year-old from Melbourne has alopecia, a rare auto-immune disease where the body’s immune system attacks the hair follicles. There is no cure and most sufferers are diagnosed before their 20th birthday.

“I remember my mum was brushing my hair one day and my hair sort of came out in clumps in the sink. I said ‘Oh no, what’s happening?’ because I didn’t know what it was,” Stella told news.com.au.

“It started coming off in patches around the back of my head, so I wore bandannas and scarves to try and cover them up. But then the patches got bigger and then it all fell off. It felt like one day I just woke up with no hair.”

By the time she was seven, Stella was completely bald.

During Alopecia Awareness Week, the charity organisation Variety is raising awareness about its Wigs for Kids program, which funds wigs for children who have lost their hair.

Wigs made from human hair can cost $4000-$6000 (it takes 10-15 ponytails to create a single wig) but after 18 months they start to lose their hair. These handmade, custom wigs come fitted with a silicon cap to prevent itching.

Stella, who is now onto her third wig, says being able to walk down the street without attracting stares is a welcome relief.

“I just get up, put my wig on and go to school. It’s just normal now and it’s actually quite easy to style,” she said.

“I just do it on the wig stand. If you do it up too high you can see the edges, so I mainly wear it in a low pony.”

Stella’s father Andrew Hammet also has alopecia and lost his hair at age 16.

“Because Dad was a kid when his hair started falling out, I’ve always known him with no hair,” Stella said. “I’ve seen photos of him at my grandparents’ house with hair and I just thought ‘Oh, that’s weird’.”

Mr Hammet said he never expected his condition would be passed onto his daughter.

“I just thought it was a one-off thing that would only affect me,” said Mr Hammet. “When her hair started falling out I thought ‘I know exactly what’s going to happen’, which is depressing because I knew the treatments are mostly ineffective.”

He says it was heartbreaking to see his daughter feel insecure and embarrassed about her appearance.

“Adults often think kids aren’t aware of how they look and see themselves, but we soon realised that Stella didn’t like looking at herself,” he said.

“One time my wife and I went into her bedroom and she had scrawled lipstick all over her mirror in her bedroom. We said ‘What did you do that for?’ and we realised it was because she didn’t want to look at herself.”

Before Stella got her first wig in Year 3, she felt awkward around her classmates.

“Everyone else was like ‘I’m going to get a fringe tomorrow’ and I couldn’t really do that,” she said. “When I was wearing my bandannas people called me a boy.”

Mr Hammet says there were rumours flying school around about why Stella’s hair had fallen out.

“Kids were saying things like ‘Oh my god, Stella’s got cancer!’ and we wanted to address that,” he said.

So when Stella arrived at high school, she went on the front foot and decided to be open about her condition.

“I told everyone in my class,” she said. “I made a powerpoint presentation with photos, explaining what alopecia is. Everyone was really accepting, asked lots of questions. and nobody thought of me any differently.

“I thought if I didn’t do that, it would be really hard with things like sleepovers, because everyone would look at me like ‘What’s wrong with her?’ Now they say to me ‘Hey Stella, how’s your hair going?’”

Dr Anne Halbert from the department of paediatric dermatology at Princess Margaret Hospital says hair loss can be especially distressing for children.

“Many children who are diagnosed with alopecia face a devastating reality. Hair loss can have aprofound negative psychological impact on them due to self-imposed isolation from normal day-to-day life,” said Dr Halbert.

“A specialised wig can allow kids with hair loss to live a normal life, relieving much of the exclusion they can feel.”

The Variety Wigs for Kids program provides specialised wigs to kids whose parents can’t afford to buy one.

“One specialised can wig cost up to $6000 and lasts two to three years so the cost is prohibitive for many families,” said Variety CEO Tam Johnston.

“The wigs are fitted to each child’s head, with customised colour, length and style. This program is just one of the many ways Variety helps kids who are sick, disadvantaged or have special needs.”

To donate your hair or to apply for wig funding visit variety.org.au

National Alopecia Areata Foundation

Source

alopecia report

Asia Pacific Alopecia Treatment Market

/in /by

Asia Pacific Alopecia Treatment Market to Reach US$ 2,655.9 Mn by 2024, Driven by Increasing Prevalence of Chemotherapy Induced Alopecia By PMR

According to a latest market report published by Persistence Market Research, titled “Asia Pacific Alopecia Treatment Market 🙁 2016-2024)”, revenue from the Asia Pacific alopecia treatment market is expected to expand at a CAGR of 6.6% during the forecast period 2016-2024.

In the report, the Asia Pacific alopecia treatment market is analyzed on the basis of, type of alopecia, treatment type, and end user.

On the basis of type of alopecia, the overall market has been segmented into alopecia areata, alopecia totalis, and alopecia universalis.

Topical drugs (creams, oils, lotions, gels, shampoos, and foam), oral drugs, injectable (platelet rich plasma therapy, steroid and injectable fillers), hair transplant services and low level laser therapy form the basis of treatment type.

By end user segment, the market has been segmented into hospitals, dermatology and trichology clinics, home care settings, and aesthetic clinics.

In the overall market, oral solid dosage formulations are expected to witness increased acceptance owing to ease of consumption by patients in Asia Pacific. Accordingly, oral drugs segment is anticiapted to witness an increase in value from US$ 556.6 Mn in 2016 to US$ 1,005.1 Mn by the end of 2024.

Rising global demand for effective hair loss treatment medications especially oral drugs is the prime driver of the market.

Oral hair loss treatment drugs are gaining popularity as they help in maintaining patient-safety through reduced number of medicine dosages, but with increased drug efficacy.

However, changing lifestyle along with increase in stress level among working class population, cosmeceutical drug manufacturers focusing on expanding their hair treatment and scalp treatment product line, and cytokine therapy gaining momentum for alopecia treatment are other factors that expected to fuel the market growth for alopecia treatment market over the forecast period.

Patent expiry of major blockbuster drugs resulting in market exclusivity for some brands and various side effects associated with the hair loss treatments is expected to hamper the overall market growth.

Some of the side effects such as allergies, depression, and chances of permanent sexual dysfunctions.

Other market deterrents include limited efficacy of the hair loss treatment drugs and lack of reimbursement facilities for hair loss treatments services, such as laser treatments.

Based on countries, the market has been divided into China, Japan, Australia & New Zealand, Malaysia, Singapore, India, Vietnam, Philippines and Rest of Asia Pacific.

Developed pharmaceuticals markets such as the China and Japan are expected to emerge as the main sourcing markets.

To View and Download TOC: http://www.persistencemarketresearch.com/market-research/asia-pacific-alopecia-treatment-market/toc

This report assesses trends by type of alopecia, treatment type, end user, and countries; to offer analytical insights about the potential demand emerging for particular alopecia treatments in specific regions.

China is estimated to dominate the alopecia treatment market accounting for maximum revenue share of the overall market by end of 2016.

By 2024 end, China and Japan markets are expected to account for over three-fifth share of the Asia Pacific alopecia treatment market revenue. In terms of market share by value, China is estimated to retain its dominant position, registering a CAGR of 7.1% over the forecast period.

Some key companies covered in this report include Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Johnson & Johnson, Inc., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd, Shiseido Co., Ltd., and Zhangguang 101 Science & Technology Co., Ltd.

These companies are primarily focused on enhancing their product portfolio through research and development and introduction of innovative and cost-effective advanced manufacturing procedures in order to gain higher market share and to strengthen their respective positions in the Asia Pacific market.

Key Players

  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Johnson & Johnson, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Cipla Ltd.
  • Cellmid Ltd.
  • The Himalaya Drug Company
  • Taisho Pharmaceutical Holdings Co., Ltd
  •  Shiseido Co., Ltd.
  • Zhangguang 101 Science & Technology Co., Ltd.

About Us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources.

By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Source

Alopecia

Alopecia Market Projected to be 11.8 Billion By 2024

/in /by

Alopecia Market Projected to be Worth $11.8 Billion By 2024

The global alopecia market was valued at over USD 7.3 billion in 2015. Key factors attributing to the growth of the alopecia market include the increasing prevalence of various chronic diseases such as arthritis, depression, PCOS, diabetes mellitus, hypertension, and cancer, easy access to scalp treatment, and the research & development of several alopecia treatment products.

Changing lifestyles of people such as the increasing consumption of alcohol, tobacco, and other associated products, increasing stress levels, and the rapidly increasing geriatric population are expected to boost the alopecia treatment market during the forecast period.

The increasing disposable incomes coupled with the rising celebrity culture and the increased emphasis being laid on aesthetic appearance; these factors altogether are contributing to the alopecia treatment market growth.

Additionally, technological advancements on the ground of product development of novel therapeutic options are some other important drivers of the alopecia market.

The increasing level of air and water pollution and genetic disorders are also leading to the increasing prevalence of hair loss.

The introduction of robust and rapid acting JAK drugs approved by the FDA, the development of methods to stimulate hair growth using human pluripotent stem cells, the development of PRP treatment, the introduction of a new drug, SM04554 which specifically stimulates hair growth in men are some of the recent technological trends in the alopecia treatment market.

North America Alopecia Treatment Market Estimates and Forecasts, by Treatment Type, 2013 – 2024 (USD Million)

Alopecia Market

Treatment Insights

Key treatments for alopecia include oral treatments, topical treatments, and others. In 2015, topical treatment held the majority of the share in alopecia treatment market accounting for over USD 1.0billion in 2015.

Topical treatment generally includes topical corticosteroids, which are available in the form of lotions, gels, and liquids.

The large share of topical treatments is attributed to the high absorbability and non-invasive nature of these treatments, which are the highest impact rendering drivers of this market. However, oral treatments are expected to witness high growth over the forecast period. The two major brands of the alopecia products are Rogaine and Propecia.

Some other brands include Viviscal, Kirkland, Phyto, Amplixin, Ultrax, Proscar, and others. Propecia is used widely since it is found to be more effective in stimulating the growth of damaged hair follicles and is approved by the U.S. FDA. Additionally, it is available in two forms namely liquid and foam, thus it is easy to apply and has minimal side effects.

Gender Insights

Alopecia is most common in men than in women. In the U.S. about 35 million men and 21 million females suffer from hair loss. While in China there are about 21% of males and 6% of females suffering from hair loss. More than 95% of men suffer from androgenetic alopecia.

The major underlying reason is the growing male geriatric population and the smoking habits of men. However, low awareness levels amongst the male population are one of the key factors for the large share of women population in the alopecia treatment market.

In women Polycystic Ovary Syndrome (PCOS) is frequent and it causes hormonal imbalance which leads to androgenetic alopecia. Traction alopecia is also commonly encountered in women due to the increased stress on hair follicles created by certain hairstyles.

In 2015, the alopecia therapeutics in women accounted for over USD 1,370 million and is expected to continue its dominance over the forecast period. High awareness amongst women population pertaining to the hair treatments are the key factors accounting for the large share of the women population seeking therapeutics for alopecia. Alopecia Areata and Telogen Effluvium alopecia are other common types of alopecia found in both men as well as women.

Regional Insights

Key regional markets included in the alopecia treatment market are North America, Asia Pacific, Europe, Latin America, and MEA. In 2015, North America accounted for the majority of the market share and was the highest revenue generating region with the revenue of over USD 2,480 million.

The presence of technologically advanced healthcare infrastructure, high disposable income, and the availability of novel therapeutic options pertaining to the alopecia treatments are few factors contributing to the high market share of the region. Additionally, the high prevalence and the proportionally high treatment rates pertaining to hair loss in the U.S. are high impact drivers for the North America Alopecia therapeutics market.

However, Asia Pacific is expected to grow at a lucrative CAGR of 5.3% over the coming eight years. The large population suffering from alopecia and the rising awareness levels pertaining to the available therapeutic options is one of the key factors for the region’s high growth rate. The economic development coupled with the constantly rising disposable income in countries such as China, India, and Singapore will present high growth opportunities. The recent innovations and technological trends in alopecia treatment, the increasing healthcare expenditures, and the augmented healthcare facilities are expected to boost the alopecia treatment market.

Competitive Market Share Insights

The key players operating in the alopecia treatment market includes Cipla, Merck & Co., Johnson & Johnson, Lifes2good, Dr. Reddy’s Laboratories, Sun Pharma, Kirkland Signature, Alpecin, Vitabiotics, and Phyto Ales Group.

The increasing research and development efforts to enhance alopecia treatments, the strategic initiatives taken by the key players of the market, and the FDA approval obtained for certain products are the major competitive strategies paving towards the alopecia market expansion. In April 2016, Johnson & Johnson declared the launch of a new global healthcare initiative to provide healthcare solutions, in Africa. In January 2016, Cipla announced that they have 200 drugs under development, of which 50 drugs have the potential to generate USD 30 billion.

Source

alopecia trial

New Treatment for Alopecia Areata

/in /by

Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata

Concert Pharmaceuticals, Inc today announced that it has initiated its Phase 1 clinical program for CTP-543, which is being developed for the treatment of alopecia areata, an autoimmune disease for which there are currently no approved treatments.

CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib, which is commercially available under the name Jakafi® in the United States for the treatment of myelofibrosis and polycythemia vera.

Ruxolitinib has been used to treat alopecia areata in academic settings, including an investigator-sponsored clinical trial, and has been shown to promote hair growth in individuals with moderate to severe disease.

Concert’s Phase 1 program will assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of single- and multiple-ascending doses of CTP-543 in healthy volunteers.

“Alopecia areata is a disease that can have devastating effects on patients but which currently lacks approved and effective therapies.

We are pleased to broaden Concert’s pipeline of clinical drug candidates with the advancement of CTP-543 into clinical testing. CTP-543 is another example of how we have applied our novel deuterium platform to create medicines that represent new treatment options,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.

“Recent advances in our understanding of alopecia areata biology, combined with patient data from several investigator-initiated studies, give us confidence that CTP-543 has potential to be an effective treatment.

We hope to move this program quickly through Phase 1 evaluation in order to initiate efficacy studies in patients with alopecia areata next year.”

The Phase 1 program is expected to enroll approximately 80 healthy volunteers. Dosing has been initiated to assess the safety, tolerability, and pharmacokinetics of single-ascending oral doses of CTP-543 in a double-blind trial compared to placebo.

Following successful completion of the first part of the Phase 1 trial, Concert will assess CTP-543 dosed orally once-daily or twice-daily for seven consecutive days in a double-blind, placebo-controlled, multiple-ascending dose trial. Pharmacodynamics of CTP-543 will also be assessed after a single dose and after 7 days of dosing in the multiple-ascending dose trial.

The Company expects to report top-line data upon completion of the multiple-dose Phase 1 program in the fourth quarter of 2016 and initiate a Phase 2 efficacy study in early 2017.

Additional information is available at www.clinicaltrials.gov.

About Alopecia Areata

Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men.

Alopecia areata can be associated with serious psychological consequences, including anxiety and depression.

There are currently no drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of alopecia areata.

In 2015, the FDA selected alopecia areata as one of eight new disease areas that it will focus on under its Patient-Focused Drug Development Initiative (PFDDI) meeting during fiscal year 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy.

The Company is developing a broad pipeline targeting genetic diseases, autoimmune disorders, CNS disorders and inflammatory diseases, among others.

For more information, please visit www.concertpharma.com.

References
1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Source

market research alopecia

Alopecia Clinical Review

/in /by

Alopecia Clinical Review, Market Growth, Segment, Trends and Forecast 2016 – 2020

“Alopecia Worldwide 2016 Clinical Trials Review, H2″ includes an complete overview of Alopecia scenario.

This Alopecia report provides data relating on Alopecia clinical trials scenario across globe.

Alopecia report also includes an review of trial numbers and also their ( Alopecia ) average enrollment in uppermost countries which are conducted globaly on Alopecia scenario.

This Alopecia report also covers disease clinical trials by country (G7 & E7), Alopecia trial status, sponsor type, region and end points status on Alopecia scenario.

GlobalData’s clinical trial report, “Alopecia Global Clinical Trials Review, H1, 2016″ provides an overview of Alopecia clinical trials scenario.

This report provides top line data relating to the clinical trials on Alopecia.

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database.

Report Alopecia also Includes prominent drugs for in-progress trials – on Alopecia scenario.(Note: based on number of ongoing trials).

Scope of Alopecia Report:-

1. This report ( Alopecia Worldwide 2016 Clinical Trials ) includes a snapshot of global clinical trials landscape on Alopecia scenario.

2. Report on Alopecia also provides top level data related to the worldwide clinical trials by country (G7 & E7), trial status, sponsor type, region as well as end points status on Alopecia scenario.

3. Alopecia Global 2016 Clinical Trials – Report reviews top companies involved in Alopecia and provides enlists all trials (Trial title, Phase, and Status) pertaining to the company on Alopecia scenario.

4. This report provides all the unaccomplished trials on Alopecia scenario with reason for unaccomplishment on Alopecia .

5. Report on Alopecia provides enrollment trends for the past five years – on Alopecia scenario.

6. Report provides latest news relted to Alopecia for the past three months.

7. Report Also Includes Top news in past 3 months on Alopecia clinical trials review scenario.

Reasons to buy

– Assists in formulating key business strategies with regards to investment

– Helps in identifying prominent locations for conducting clinical trials which saves time and cost

– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

– Supports understanding of trials count and enrollment trends by country in global therapeutics market

– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

– Facilitates clinical trial assessment of the indication on a global, regional and country level

 

CTP-543 alopecia

CTP-543 for Treatment of Alopecia Areata

/in /by

Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata

Concert Pharmaceuticals, Inc today announced its next product candidate, CTP-543, for the treatment of alopecia areata. Alopecia areata is an autoimmune disease characterized by patchy or widespread hair loss, for which there is significant unmet medical need and currently no FDA-approved treatment.

CTP-543 is a deuterium-modified analog of ruxolitinib, which selectively inhibits Janus kinases 1 and 2, known as JAK1 and JAK2.

Ruxolitinib is commercially available under the name Jakafi® in the United States for the treatment of myelofibrosis and polycythemia vera.

Concert expects to initiate Phase 1 clinical evaluation of CTP-543 in the second quarter of 2016 with efficacy studies commencing in 2017.

Ruxolitinib has been used to treat alopecia areata in academic settings, including an investigator-sponsored clinical trial, and has been shown to promote hair growth in individuals with moderate to severe disease.

Preclinical studies conducted by the Company demonstrated that CTP-543 retains ruxolitinib’s selective JAK 1/2 inhibition profile and shows improved metabolic stability.

“We are very excited about the potential of CTP-543 to greatly enhance patient care for individuals with alopecia areata. CTP-543 represents an opportunity to address an important disease where new and effective treatment options are needed,” said Roger Tung, Ph.D.,

President and Chief Executive Officer of Concert Pharmaceuticals. “Based on demonstrated clinical activity of ruxolitinib in alopecia areata, CTP-543 has the potential to become an important first-in-class oral medicine to treat a devastating condition affecting millions of people in the U.S.”

Recently, the U.S. Patent and Trademark Office issued U.S. Patent No. 9,249,149 that claims CTP-543 as a novel composition of matter.

“CTP-543 is a prime example of the application of our deuterium platform to create proprietary new medicines which enhance and extend the utility of known molecules into new therapeutic areas.

We believe we have developed a valuable, potentially first-in-class new drug candidate for an important unmet medical need and look forward to advancing CTP-543 into clinical evaluation shortly,” said Dr. Tung.

About Alopecia Areata

Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body.

The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.

Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression.

According to MD Anderson, nearly 2% of people in the United States, including both adults and children, suffer from alopecia areata.

There are currently no drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of alopecia areata.

In 2015, the FDA selected alopecia areata as one of eight new disease areas that it will focus on under its Patient-Focused Drug Development Initiative (PFDDI) meeting during fiscal year 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.

Conference Call and Webcast

The Company will host a conference call and webcast tomorrow, May 5, 2016 at 8:30 a.m. EDT to discuss first quarter financial results and the CTP-543 program.

A live webcast may be accessed in the Investors section of the company’s website at www.concertpharma.com.

Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert’s website for three months.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs.

This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy.

The Company is developing a broad pipeline targeting genetic diseases, autoimmune disorders, CNS disorders and inflammatory diseases, among others.

For more information, please visit www.concertpharma.com.

Source